Valneva Shares Bounce Back 2% After a 39% Plunge Over Three Months

Current Trading Session

In today's session, Valneva is trading at 2.70 euros, up 1.97% compared to yesterday's close of 2.64 euros. Over the week, the stock has gained 4.7%, contrasting with the downward trajectory of the past months: the decline reaches 39.17% over three months and 15.54% over a year. Technically, the RSI is at 29, a level generally associated with an oversold zone, which may explain the rebound observed this morning. The price is also significantly below its 50-day and 200-day moving averages, located at 3.97 euros and 3.89 euros respectively, confirming the underlying bearish trend. The nearest support is at 2.58 euros, a threshold around which the stock was still hovering recently. In the European pharmaceutical sector, Sanofi is up 1.05% in the session, while UCB remains stable. The CAC 40 is down 0.63% at 8275 points, thus not providing support to the Paris market this morning.

Critical Weeks Ahead

The upcoming weeks are crucial for the Franco-Austrian biotech. The publication of the first quarter 2026 results, scheduled for May 7, will be a key moment to assess the commercial momentum of its vaccines, particularly against chikungunya and Japanese encephalitis. The general assembly, scheduled for June 1, will complete this sequence. With a significantly reduced capitalization after months of decline, the stock is trading in the lower part of its Bollinger Bands, at about 35% of the total amplitude between the lower bound (1.51 euros) and the upper bound (4.92 euros). This position reflects persistent selling pressure on the stock, despite the rebound observed at the beginning of the week. On the other side of the Atlantic, major pharmaceutical companies showed contrasting trajectories at the close of the day: AbbVie was up 1.84% and Johnson & Johnson 0.90%, while Eli Lilly was down 0.76%.